All Programs

Use the tool below to view all available Prova Series

MinuteCE®
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
1.00 credit 10 episodes
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 credit 10 episodes
Shared Goals, Shared Gains: Align With Patient Preferences
Shared Goals, Shared Gains: Align With Patient Preferences
MinuteCE®
Shared Goals, Shared Gains: Align With Patient Preferences
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
The IgG Clock: Redose Using IgG Kinetics
The IgG Clock: Redose Using IgG Kinetics
MinuteCE®
The IgG Clock: Redose Using IgG Kinetics
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
Target Locked in gMG: Why T2T Matters
Target Locked in gMG: Why T2T Matters
MinuteCE®
Target Locked in gMG: Why T2T Matters
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
CME/CE In-Person & Virtual Event
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
April 13, 2026
Pittsburgh, Pennsylvania
1.00 credit Learn more
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
CME/CE Virtual Event
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
April 13, 2026
12:00 PM - 01:00 PM ET
1.00 credit Learn more
CME/CE In-Person Event
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
April 13, 2026
Pittsburgh, Pennsylvania
1.00 credit Learn more
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
CME/CE
Shifting the Script: Personalizing Overactive Bladder Treatment in Complex Patients
0.25 credits
- David Staskin, MD
- Matt T. Rosenberg, MD
- Kennedy Koebbe, MSN, RN
0.25 credits
Mechanism-Based Targeting: Why APRIL Matters in IgAN
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®
Mechanism-Based Targeting: Why APRIL Matters in IgAN
1.00 program credit
- Suzuki Yusuke, MD, PhD
- Dana Rizk, MD
1.00 program credit
APRIL Uncovered: An Upstream Driver in IgAN
APRIL Uncovered: An Upstream Driver in IgAN
MinuteCE®
APRIL Uncovered: An Upstream Driver in IgAN
1.00 program credit
- Dana Rizk, MD
- Hong Zhang
1.00 program credit
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
CME/CE
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
0.25 credits
- María-Victoria Mateos, MD, PhD
0.25 credits
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CE
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
0.25 credits
- María-Victoria Mateos, MD, PhD
- Luciano Costa, M.D., Ph.D.
0.25 credits
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CE
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
0.50 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Cristina Rodriguez, MD
0.50 credits
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
MinuteCE®
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
0.75 program credits
- Eileen M. O'Reilly, MD
0.75 program credits
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
0.75 program credits
- Kathryn Arbour
0.75 program credits
MinuteCE®
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
0.75 credits 8 episodes
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 credits 8 episodes

All Programs

Popular

Title

Share on ReachMD